Sonoma Pharmaceuticals
SNOA
22 hedge funds and large institutions have $2.73M invested in Sonoma Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
22% more funds holding
Funds holding: 18 → 22 (+4)
0.01% more ownership
Funds ownership: 0.08% → 0.09% (+0.01%)
21% less capital invested
Capital invested by funds: $3.44M → $2.73M (-$708K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$316K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$69K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$54.2K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$50.1K |
| 5 |
PGA
Premia Global Advisors
Coral Gables,
Florida
|
+$46K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
Bard Associates
Chicago,
Illinois
|
-$28.8K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$22.2K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$3K |
SNOA Hedge Fund Activity: Q1 2018 in Review
22 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q1 2018, worth a combined $2.73M — down 21% from $3.44M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new SNOA positions and 1 closed out — a net gain of 4 holders — while 6 added to existing stakes and 2 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $316K. The largest seller was Bard Associates, cutting an estimated $28.8K.
- 22 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q1 2018, up from 18 in Q4 2017.
- Funds reported $2.73M of Sonoma Pharmaceuticals stock for Q1 2018, down 21% quarter-over-quarter.
- 5 funds opened new Sonoma Pharmaceuticals positions in Q1 2018 and 1 closed out, a net change of +4 holders.
- The largest Sonoma Pharmaceuticals buyer in Q1 2018 was Sabby Management, an estimated $316K added.
- The largest Sonoma Pharmaceuticals seller in Q1 2018 was Bard Associates, an estimated $28.8K sold.
Based on aggregated 13F filings for Q1 2018.